Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous MUC1-activated T cells

A preparation of autologous T lymphocytes that have been activated against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential immunomodulating and antineoplastic activities. Upon re-introduction into the patient, autologous MUC1-activated T cells specifically recognize and induce selective toxicity in MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous MUC1-activated T lymphocytes
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search